Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and simvastatin combination therapy to ABT-335 and simvastatin monotherapy in subjects with mixed dyslipidemia.

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 and simvastatin combination therapy to ABT-335 and simvastatin monotherapy in subjects with mixed dyslipidemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Choline fenofibrate (Primary) ; Simvastatin (Primary)
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 16 Jun 2010 Results of the 52-week extension study have been presented at the 17th World Congress of Cardiology.
    • 01 Apr 2009 Patient numbers amended from 560 to 657 as reported by ClinicalTrials.gov.
    • 31 Mar 2008 Results were presented at the 57th Annual meeting of the American College of Cardiology; the primary endpoint was met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top